Biostage highlights first-in-human esophageal success, FDA-approved IND, founder CEO return

Harvard Apparatus Regenerative Technology, Inc.

First-in-human esophageal implant at Mayo Clinic; paper published Aug 2021 concludes 'considerable clinical use'.
FDA-approved IND for Phase 1/2 trial (10 patients); two orphan-drug designations provide 7-year exclusivity.
Founder David Green returned as interim CEO and Chairman in Nov 2021; invested $250k in BSTG; compensation in options.
Cash ~$1.7M as of Nov 30, 2021; burn ~$250k/month; goals include raising capital, commencing trial, NASDAQ uplist.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.